Millennium: The Takeda Oncology Company announced publication of an article in the journal Molecular Cell describing the mechanism of enzyme inhibition of MLN4924-a small molecule inhibitor of the NEDD8-Activating Enzyme (NAE), a key component of a protein homeostasis pathway. MLN4924 is the first small molecule inhibitor that specifically targets this class of enzyme to be studied clinically, and is currently being studied in Phase I clinical trials. NAE is an enzyme that modulates the level of proteins critical for the regulation of cancer cell growth and survival pathways...
More...
More...